As banks navigate a landscape scarred by the Synapse bankruptcy, they need to build or buy the technical ability to reconcile accounts daily and vet any new fintech partners more thoroughly.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

Quisitive Technology Solutions, Inc. (CVE:QUIS – Get Free Report) has received an average recommendation of “Moderate Buy” ...